Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Daclatasvir in Children With HCV
NCT07905989Completed
- Sponsor
- National Liver Institute
- Start
- Dec 2023
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial of sofosbuvir and daclatasvir in hepatitis C (HCV), sponsored by National Liver Institute. Primary endpoints: Number of patients with Headache at 12 weeks, Number of patients with fatigue at 12 weeks and 12 more. Started Dec 2023; status: completed.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT07905989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07905989.